Brief: Armata Pharmaceuticals Announces Clearance Of Investigational New Drug Application For Phase 2 Trial Of AP-Pa02
22/02/2022 13:54
Feb 22 (Reuters) - Armata Pharmaceuticals Inc ARMP.A :
* ARMATA PHARMACEUTICALS ANNOUNCES CLEARANCE OF
INVESTIGATIONAL
NEW DRUG APPLICATION TO INITIATE PHASE 2 CLINICAL TRIAL OF
AP-PA02 IN NON-CYSTIC FIBROSIS BRONCHIECTASIS
Source text for Eikon: ID:nPn58JKvha
Further company coverage: ARMP.A
((reuters.briefs@thomsonreuters.com;))
Recent news on Armata Pharmaceuticals
See all newsBrief: Armata Pharmaceuticals Announces First Quarter 2026 Results And Provides Corporate Update
Brief: Armata Pharmaceuticals Delays Announcement Of Fourth Quarter And Full-Year 2025 Results And Provides Corporate Update
Brief: Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product Designation
Armata Pharma jumps on US FDA nod for late-stage infection trial
Brief: Armata Pharmaceuticals Commissions cGMP Manufacturing Facility In Los Angeles